Dicerna to Participate in Two Upcoming Investor Conferences
24 September 2018 - 9:30PM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading
developer of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will participate in two
investor conferences in October.
- 2018 Cantor Fitzgerald Global
Healthcare Conference, Monday, October 1, 2018 at 7:45 a.m. ET at
the InterContinental New York Barclay in New York. Dr. Fambrough
will present a corporate update and overview of the Company’s most
advanced GalXC™ pipeline programs, including DCR-PHXC, an
investigational RNAi therapeutic in development for the treatment
of all forms of primary hyperoxaluria. A live webcast of the
presentation can be accessed on the Investors & Media section
on the Dicerna website at www.dicerna.com. An archived replay of
the webcast will be available on the Company’s website after the
conference.
- Leerink Partners Roundtable Series:
Rare Disease and Oncology, Tuesday, October 2, 2018 at 2:30 p.m. ET
at the Lotte New York Palace in New York. Dr. Fambrough will
participate in an analyst-moderated fireside chat. A live webcast
of the fireside chat can be accessed on the Investors & Media
section on the Dicerna website at www.dicerna.com. An archived
replay of the webcast will be available on the Company’s website
after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative,
subcutaneously delivered RNAi-based therapeutics for the treatment
of diseases involving the liver, including rare diseases, chronic
liver diseases, cardiovascular diseases, and viral infectious
diseases. Dicerna is leveraging its proprietary GalXC™ RNAi
technology platform to build a broad pipeline in these core
therapeutic areas, focusing on target genes where connections
between target gene and diseases are well understood and
documented. Dicerna intends to discover, develop and commercialize
novel therapeutics either on its own or in collaboration with
pharmaceutical partners. For more information, please visit
www.dicerna.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180924005170/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Dicerna Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Dicerna Pharmaceuticals, Inc. News Articles